Atara Biotherapeutics (ATRA) Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory With cutting-edge science…
Technology - Atara Biotherapeutics As a leading allogeneic T-cell immunotherapy company, Atara is pioneering the development of transformative therapies for patients with serious diseases by leveraging our novel allogeneic Epstein Barr virus (EBV) T-cell platform
News Events :: Atara Biotherapeutics (ATRA) Mar 16, 2026 4:05 pm EDT Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress Mar 12, 2026 8:05 am EDT Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel Upcoming Events View All Events Jun 9, 2026 9:00 am PDT Annual Meeting of Stockholders
Atara Biotherapeutics Announces Third Quarter Financial Results and . . . About Atara Biotherapeutics, Inc Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory
Press Releases :: Atara Biotherapeutics (ATRA) Atara Biotherapeutics Announces U S FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
ATRA Stock - Atara Biotherapeutics Form 8937 - Organizational Actions Effective January 1, 2011, Internal Revenue Code Section 6045B requires issuers of corporate stock to provide information regarding corporate actions that affect stock basis Form 8937, Report of Organizational Actions Affecting Basis in Securities, is used to report such information FORM 8937: 6 20 2024 Reverse Stock Split